Tareq Al Baghdadi
Overview
Explore the profile of Tareq Al Baghdadi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
710
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Eskander R, Sill M, Beffa L, Moore R, Hope J, Musa F, et al.
Nat Med
. 2025 Mar;
PMID: 40044930
Historically, the treatment of patients with advanced stage or recurrent endometrial cancer included paclitaxel plus carboplatin. Immunotherapy in combination with chemotherapy resulted in improved clinical outcomes in several solid tumors....
2.
Jodeh D, Terzic M, Wenig E, Amin A, Baghdadi T
J Med Case Rep
. 2024 Oct;
18(1):532.
PMID: 39478563
Background: Leptomeningeal metastasis occurs in 5% of patients with prostate cancer and indicates a very poor prognosis. Case Presentation: A 60-year-old Caucasian male patient diagnosed with metastatic castration-resistant prostate cancer...
3.
Alvarez J, Shi Q, Dasari A, Garcia-Aguilar J, Sanoff H, George T, et al.
BMC Cancer
. 2024 Jul;
24(1):901.
PMID: 39060961
Background: Recent data have demonstrated that in locally advanced rectal cancer (LARC), a total neoadjuvant therapy (TNT) approach improves compliance with chemotherapy and increases rates of tumor response compared to...
4.
Smith M, Jegede O, Martin P, Till B, Parekh S, Yang D, et al.
Blood
. 2024 May;
144(10):1083-1092.
PMID: 38820500
Although initial therapy of mantle cell lymphoma (MCL) is not standardized, bendamustine plus rituximab (BR) is commonly used in older patients. Rituximab (R) maintenance after induction is often used. Thus,...
5.
Calfa C, Rothe M, Mangat P, Garrett-Mayer E, Ahn E, Burness M, et al.
JCO Precis Oncol
. 2024 Feb;
8:e2300513.
PMID: 38354330
Purpose: The Targeted Agent and Profiling Utilization Registry Study is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and...
6.
Duvivier H, Rothe M, Mangat P, Garrett-Mayer E, Ahn E, Baghdadi T, et al.
J Clin Oncol
. 2023 Aug;
41(33):5140-5150.
PMID: 37561967
Purpose: The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a pragmatic basket trial evaluating antitumor activity of approved targeted agents in patients with advanced cancers harboring potentially actionable...
7.
Gorak E, Otterstatter M, Baghdadi T, Gillis N, Foran J, Liu J, et al.
Blood Adv
. 2023 Aug;
7(20):6120-6129.
PMID: 37552083
Myelodysplastic neoplasms (MDS) are a collection of hematopoietic disorders with widely variable prognoses and treatment options. Accurate pathologic diagnoses present challenges because of interobserver variability in interpreting morphology and quantifying...
8.
Hall W, Li J, You Y, Gollub M, Grajo J, Rosen M, et al.
J Clin Oncol
. 2023 Jul;
41(29):4643-4651.
PMID: 37478389
Purpose: Total neoadjuvant therapy (TNT) is a newly established standard treatment for rectal adenocarcinoma. Current methods to communicate magnitudes of regression during TNT are subjective and imprecise. Magnetic resonance tumor...
9.
Schrag D, Shi Q, Weiser M, Gollub M, Saltz L, Musher B, et al.
N Engl J Med
. 2023 Jun;
389(4):322-334.
PMID: 37272534
Background: Pelvic radiation plus sensitizing chemotherapy with a fluoropyrimidine (chemoradiotherapy) before surgery is standard care for locally advanced rectal cancer in North America. Whether neoadjuvant chemotherapy with fluorouracil, leucovorin, and...
10.
Abel G, Hebert D, Lee C, Rollison D, Gillis N, Komrokji R, et al.
Blood Adv
. 2023 May;
7(14):3506-3515.
PMID: 37146263
Health-related quality of life (HRQoL) and vulnerability are variably affected in patients with myelodysplastic syndromes (MDS) and other cytopenic states; however, the heterogeneity of these diseases has limited our understanding...